Once‐daily administration of trospium chloride extended release provides 24‐hr coverage of nocturnal and diurnal symptoms of overactive bladder: An integrated analysis of two phase III trials

Once‐daily extended release (XR) trospium chloride, which provides therapeutic trospium plasma concentrations over 24 hours, has demonstrated efficacy in treating overactive bladder (OAB) symptoms as evaluated over a 24‐hr period. This analysis examined the effects of trospium XR on diurnal and nocturnal OAB symptoms.

[1]  Sum Lam,et al.  Pharmacologic management of overactive bladder , 2007, Clinical interventions in aging.

[2]  J. J. de la Rosette,et al.  Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? , 2009, Current opinion in urology.

[3]  R. Asplund.  Nocturia in relation to sleep, health, and medical treatment in the elderly , 2005, BJU international.

[4]  R G Marks,et al.  Nocturia: A Risk Factor for Falls in the Elderly , 1992, Journal of the American Geriatrics Society.

[5]  R. Dmochowski,et al.  Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. , 2008, Urology.

[6]  C. Tannenbaum,et al.  Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence , 2009, Current opinion in urology.

[7]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[8]  S. Colman,et al.  A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. , 2005, The Journal of urology.

[9]  K. Coyne,et al.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study , 2008, BJU international.

[10]  P. Abrams,et al.  Understanding the elements of overactive bladder: questions raised by the EPIC study , 2008, BJU international.

[11]  R. Dmochowski,et al.  Trospium chloride once‐daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials , 2009, International journal of clinical practice.

[12]  R. Dmochowski,et al.  Extended-release trospium chloride improves quality of life in overactive bladder. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  J. Donovan,et al.  Urinary symptoms and incontinence in women: relationships between occurrence, age, and perceived impact. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[14]  T. Wagner,et al.  Health-related consequences of overactive bladder. , 2002, The American journal of managed care.

[15]  P. Abrams,et al.  Muscarinic receptor antagonists for overactive bladder , 2007, BJU international.

[16]  R. Scarpa.  Lower Urinary Tract Symptoms: What Are the Implications for the Patients? , 2001, European Urology.

[17]  J. J. de la Rosette,et al.  Role of muscarinic receptor antagonists in urgency and nocturia , 2005, BJU international.

[18]  N. Silver,et al.  Pharmacokinetics of Once‐Daily Trospium Chloride 60 mg Extended Release and Twice‐Daily Trospium Chloride 20 mg in Healthy Adults , 2010, Journal of clinical pharmacology.

[19]  R. Lipton,et al.  Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. , 2001, Urology.

[20]  P. Sand,et al.  Nocturia: Etiology, diagnosis, and treatment , 2008, Neurourology and urodynamics.

[21]  C. Thompson,et al.  The prevalence of nocturia and its effect on health‐related quality of life and sleep in a community sample in the USA , 2003, BJU international.

[22]  R. Dmochowski,et al.  Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. , 2007, The Journal of urology.

[23]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[24]  S. Madersbacher,et al.  Nocturia is an age‐independent risk factor for hip‐fractures in men , 2009, Neurourology and urodynamics.

[25]  Z. Gabriel,et al.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. , 2008, European urology.

[26]  E. Vittinghoff,et al.  Urinary Incontinence: Does it Increase Risk for Falls and Fractures? , 2000, Journal of the American Geriatrics Society.

[27]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.